These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 8121441)
41. Intracoronary coagulative nightmare during recanalization of a recent total occlusion of the left anterior descending artery. Paolillo V; Gastaldo D J Invasive Cardiol; 2004 Feb; 16(2):72-5. PubMed ID: 14760195 [No Abstract] [Full Text] [Related]
42. Rheolytic thrombectomy: a new treatment for stent thrombosis. Scott LR; Silva JA; White C; Collins TJ Catheter Cardiovasc Interv; 1999 May; 47(1):97-101. PubMed ID: 10385170 [TBL] [Abstract][Full Text] [Related]
43. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off? Jeremias A; Gruberg L J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401 [No Abstract] [Full Text] [Related]
44. Comparison of angioplasty with stenting in acute myocardial infarction. Herrmann HC N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478 [No Abstract] [Full Text] [Related]
45. Different benefits, different risks, equal cost. Colombo A Eur Heart J; 1999 Nov; 20(21):1531-2. PubMed ID: 10529320 [No Abstract] [Full Text] [Related]
51. Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting? Khan JM; Watson RD; Varma C; Millane T; Lip GY Int J Clin Pract; 2006 Apr; 60(4):498-9. PubMed ID: 16620368 [No Abstract] [Full Text] [Related]
52. Instant dissolution of intracoronary thrombus by abciximab. Lee CH; Ho KT; Tan HC Int J Cardiol; 2005 Sep; 104(1):102-3. PubMed ID: 16137518 [TBL] [Abstract][Full Text] [Related]
53. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications. Mayer DM; Docktor WJ Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118 [No Abstract] [Full Text] [Related]
54. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780 [TBL] [Abstract][Full Text] [Related]
55. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. Moliterno DJ; Ziada KM J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681 [No Abstract] [Full Text] [Related]
56. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies]. Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692 [No Abstract] [Full Text] [Related]
57. Management of coronary artery perforation in patients receiving abciximab. Del Campo C; Zelman R Catheter Cardiovasc Interv; 2001 Sep; 54(1):139-40. PubMed ID: 11553964 [No Abstract] [Full Text] [Related]
59. Integrin beta3 blockade with abciximab and protection from myocardial ischemic events. Conrad ME; Umbreit JN; Moore EG JAMA; 1998 Jan; 279(3):195-6. PubMed ID: 9438735 [No Abstract] [Full Text] [Related]
60. Intravenous administration of monoclonal antibody to the platelet GP IIb/IIIa receptor to treat abrupt closure during coronary angioplasty. Anderson HV; Revana M; Rosales O; Brannigan L; Stuart Y; Weisman H; Willerson JT Am J Cardiol; 1992 May; 69(16):1373-6. PubMed ID: 1585878 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]